Exploring the Role of GLP-1 Receptor Agonists in Alzheimer’s Disease: A Review of Preclinical and Clinical Evidence
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including dulaglutide, liraglutide, semaglutide, and exenatide, are effective treatments for type 2 diabetes mellitus (T2DM) and obesity. These agents mimic the action of the endogenous incretin glucagon-like peptide-1 (GLP-1) by enhancing insuli...
Saved in:
| Main Authors: | Lívia C. R. Teixeira, Marcelo R. Luizon, Karina B. Gomes |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Receptors |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2813-2564/4/1/2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation
by: Giulia Migliorisi, et al.
Published: (2025-07-01) -
Glucagon-like peptide 1 receptor agonists: A new approach to type 2 diabetes management
by: Lynn Lambert
Published: (2013-12-01) -
REBOUND OBESITY AFTER GLP-1 AGONISTS DISCONTINUATION
by: Zainab M. Al-Shammaa, et al.
Published: (2025-07-01) -
Decreased incidence of hidradenitis suppurativa and psoriasis in diabetic patients treated with GLP-1 receptor agonists: A retrospective cohort study
by: Lauren M. Ching, BS, et al.
Published: (2025-10-01) -
Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment
by: Rui Salvador, et al.
Published: (2025-03-01)